前立腺癌の予防と治療：各種技術と世界市場

世界の前立腺癌ケアの市場規模は、2023年の379億米ドルから、予測期間中は8.3%のCAGRで推移し、2028年末には564億米ドルの規模に成長すると予測されています。

世界の前立腺癌医薬品の市場規模は、2023年の175億米ドルから、予測期間中は11.0%のCAGRで推移し、2028年末には296億米ドルの規模に成長すると予測されています。また、前立腺癌スクリーニングおよび検出の市場規模は、2023年の150億米ドルから、5.8%のCAGRで推移し、2028年末には198億米ドルに成長すると予測されています。

当レポートでは、世界の前立腺癌ケアの市場を調査し、市場概要、疾患および治療の概要、市場影響因子の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、技術動向、パイプラインの分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 市場概要

• 癌の概要
• 前立腺癌
• 前立腺癌の生物学
• 症状
• スクリーニング
• 診断
• 限局性前立腺癌
• 転移性前立腺癌
• 待機療法または監視療法
• 治療
• 総論

第4章 市場力学

• 概要
• 市場促進要因
• 前立腺癌の罹患率の増加
• 積極的な監視とスクリーニング
• 個別化治療
• 転移性去勢抵抗性前立腺癌の承認
• コラボレーションとライセンシング契約
• 市場の課題
• 独占期間の満了とジェネリック化
• 医療機関やその他のリソースの不足
• 市場機会

第5章 スクリーニングおよび診断市場：検査タイプ別

• 市場概要
• バイオマーカー検査
• PSA検査
• PSA検査の限界
• PSA上昇環境における前立腺癌の早期発見のためのバイオマーカー検査
• 直腸指検査
• DREの制限
• 前立腺生検
• 前立腺癌のグレード（グリソンスコア）
• 前立腺上皮内腫瘍
• 異型小腺房増殖
• 増殖性炎症性萎縮症
• 前立腺管内癌
• 前立腺生検の限界
• 前立腺癌の画像技術
• 前立腺癌スクリーニング/診断市場（検査タイプ別）
• バイオマーカー検査
• DRE
• 前立腺生検

第6章 医薬品市場：医薬品タイプ別

• 市場概要
• ホルモン療法
• アンドロゲン剥奪療法
• 抗アンドロゲン療法
• 前立腺癌治療におけるホルモン療法の使用
• 標的療法
• PARP阻害剤
• 放射性リガンド療法
• 低分子標的薬剤
• モノクローナル抗体
• 化学療法
• 免疫療法
• 市場収益：医薬品タイプ別
• ホルモン療法
• 標的療法
• 免疫療法
• 化学療法

第7章 手術および放射線治療市場：治療タイプ別

• 市場概要
• 積極的監視
• 根治的前立腺切除術
• ロボット前立腺切除術
• 観血的根治的前立腺切除術
• 腹腔鏡下前立腺切除術
• 根治的前立腺切除術の市場収益
• 放射線治療
• 外部ビーム放射線療法
• 近接照射療法
• 併用放射線療法
• 放射線治療装置の市場収益

第8章 地域別市場内訳

• 市場概要
• 市場収益：地域別
• 北米
• 市場収益：製品タイプ別
• 欧州
• 市場収益：製品タイプ別
• アジア太平洋
• 市場収益：製品タイプ別
• その他の地域
• 市場収益：製品タイプ別

第9章 新たな技術と開発

• 概要
• リキッドバイオプシー
• マルチパラメトリックMRI
• 相同組換え修復遺伝子変異
• 高度な放射線治療技術
• AIと機械学習

第10章 パイプライン分析

• 概要
• 企業別

第11章 競合情報

• 概要
• スクリーニング・診断市場
• 放射線治療デバイス市場
• 医薬品市場

第12章 企業プロファイル

• ABBOTT
• ACCURAY INC.
• ASTELLAS PHARMA INC.
• ASTRAZENECA PLC
• BAYER AG
• DANAHER CORP.
• DENDREON PHARMACEUTICALS LLC
• ELEKTA
• F. HOFFMANN-LA ROCHE LTD.
• JOHNSON & JOHNSON SERVICES INC.
• PFIZER INC.
• SANOFI
• SIEMENS HEALTHINEERS AG

第13章 付録：略語

List of Tables

• Summary Table : Global Market for Prostate Cancer Care, by Type, Through 2028
• Table 1 : Four Stages of Prostate Cancer
• Table 2 : Prostate Cancer: Local and Metastatic Symptoms
• Table 3 : Current Prostate Cancer Treatment Options
• Table 4 : Prostate Cancer: Major Points
• Table 5 : Estimated Number of New Prostate Cancer Cases, by Region, 2020 to 2040
• Table 6 : Key Biomarkers for Prostate Cancer
• Table 7 : First-Time Generic Drug Approvals for Prostate Cancer, 2021 to November 2023
• Table 8 : ACS, NCCN and USPSTF Guidelines on PSA Screening Tests
• Table 9 : Additional Biomarker Tests for the Early Detection/Screening of Prostate Cancer in Elevated PSA Settings
• Table 10 : NCCN and USPSTF Guidelines on Use of DRE for Prostate Cancer Screening
• Table 11 : Imaging Technologies for Prostate Cancer
• Table 12 : Prostate Cancer Screening and Diagnostic Methods
• Table 13 : Global Market for Prostate Cancer Screening and Detection, by Test Type, Through 2028
• Table 14 : Hormone Therapy Drugs Approved for Prostate Cancer Treatment
• Table 15 : PARP Inhibitors Approved for Prostate Cancer Treatment
• Table 16 : Radioligand Drugs Approved for Prostate Cancer Treatment
• Table 17 : Chemotherapy Drugs Approved for Prostate Cancer Treatment
• Table 18 : Immunotherapy Approved for Prostate Cancer Treatment
• Table 19 : Global Market for Prostate Cancer Pharmaceuticals, by Drug Type, Through 2028
• Table 20 : Global Market for Hormone Therapy Drugs for Prostate Cancer, by Drug Type, Through 2028
• Table 21 : Global Market for Targeted Therapy Drugs for Prostate Cancer, by Drug Type, Through 2028
• Table 22 : Treatment Options for Prostate Cancer
• Table 23 : Advantages and Disadvantages of Radical Prostatectomy
• Table 24 : Global Market for Radical Prostatectomy, Through 2028
• Table 25 : Comparison of Low- and High-Dose Radiation Therapy
• Table 26 : Comparison of EBRT and Brachytherapy
• Table 27 : Global Market for Radiation Therapy Devices for Prostate Cancer, by Treatment Type, Through 2028
• Table 28 : Advances in EBRT
• Table 29 : Global Market for Prostate Cancer Screening, Diagnosis and Treatment, by Region, Through 2028
• Table 30 : North American Market for Prostate Cancer Care, by Product Type, Through 2028
• Table 31 : North American Market for Prostate Cancer Screening and Detection, by Test Type, Through 2028
• Table 32 : Europe: Prostate Cancer Incidence, Mortality and Prevalence, 2020
• Table 33 : European Market for Prostate Cancer Care, by Product Type, Through 2028
• Table 34 : European Market for Prostate Cancer Screening and Detection, by Test Type, Through 2028
• Table 35 : Worldwide Number of New Prostate Cancer Cases, by Region, 2020, 2030, 2040
• Table 36 : Asia-Pacific Market for Prostate Cancer Care, by Product Type, Through 2028
• Table 37 : Asia-Pacific Market for Prostate Cancer Screening and Detection, by Test Type, Through 2028
• Table 38 : RoW Market for Prostate Cancer Care, by Product Type, Through 2028
• Table 39 : Liquid Biopsy Tests for the Early Detection/Screening of Prostate Cancer in Elevated PSA Settings
• Table 40 : PARP Inhibitors in Phase 3 Clinical Trials
• Table 41 : Companies with Two or More Active Clinical Trials in Phase 2 or 3 for Prostate Cancer, by Company, as of November 2023
• Table 42 : Prostate Cancer Drugs Pipeline (Phase III Industry Trials)
• Table 43 : Ranking of Companies in the Market for Biomarker Tests for Prostate Cancer Screening and Diagnosis, 2022
• Table 44 : Ranking of Companies in the Market for Radiation Therapy Devices for Prostate Cancer, 2022
• Table 45 : Abbott: Company Snapshot
• Table 46 : Abbott: Financial Performance, FY 2021 and 2022
• Table 47 : Abbott: Prostate Cancer Product Portfolio
• Table 48 : Accuracy Inc.: Company Snapshot
• Table 49 : Accuracy Inc.: Financial Performance, FY 2022 and 2023
• Table 50 : Accuray Inc.: Radiotherapy Product Portfolio
• Table 51 : Accuray Inc.: Recent Developments, 2022-2023
• Table 52 : Astellas Pharma Inc.: Company Snapshot
• Table 53 : Astellas Pharma Inc.: Financial Performance, FY 2021 and 2022
• Table 54 : Astellas Pharma Inc.: Prostate Cancer Drug Portfolio
• Table 55 : Astellas Pharma Inc.: Recent Developments, 2021-2023
• Table 56 : AstraZeneca Plc: Company Snapshot
• Table 57 : AstraZeneca Plc: Financial Performance, FY 2021 and 2022
• Table 58 : AstraZeneca Plc: Prostate Cancer Drug Portfolio
• Table 59 : AstraZeneca Plc: Recent Developments, 2022-2023
• Table 60 : Bayer AG: Company Snapshot
• Table 61 : Bayer AG: Financial Performance, FY 2021 and 2022
• Table 62 : Bayer AG: Prostate Cancer Drugs Portfolio
• Table 63 : Bayer AG: Recent Developments, 2021-2023
• Table 64 : Danaher Corp.: Company Snapshot
• Table 65 : Danaher Corp.: Financial Performance, FY 2021 and 2022
• Table 66 : Danaher Corp.: Prostate Health Product Portfolio
• Table 67 : Dendreon Pharmaceuticals LLC: Company Snapshot
• Table 68 : Dendreon Pharmaceuticals LLC: Prostate Cancer Drug Portfolio
• Table 69 : Elekta: Company Snapshot
• Table 70 : Elekta: Financial Performance, FY 2022 and 2023
• Table 71 : Elekta: Radiotherapy Product Portfolio
• Table 72 : Elekta: Recent Developments, 2021-2023
• Table 73 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 74 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2021 and 2022
• Table 75 : F. Hoffmann-La Roche Ltd.: Product Portfolio
• Table 76 : F. Hoffmann-La Roche Ltd.: Recent Developments, 2023
• Table 77 : Johnson & Johnson Services, Inc.: Company Snapshot
• Table 78 : Johnson & Johnson Services, Inc.: Financial Performance, FY 2021 and 2022
• Table 79 : Johnson & Johnson Services, Inc.: Prostate Cancer Drug Portfolio
• Table 80 : Johnson & Johnson Services, Inc.: Recent Developments, 2023
• Table 81 : Pfizer Inc.: Company Snapshot
• Table 82 : Pfizer Inc.: Financial Performance, FY 2021 and 2022
• Table 83 : Pfizer Inc.: Prostate Cancer Drugs Portfolio
• Table 84 : Pfizer Inc.: Recent Developments, 2022-2023
• Table 85 : Sanofi: Company Snapshot
• Table 86 : Sanofi: Financial Performance, FY 2021 and 2022
• Table 87 : Sanofi: Prostate Cancer Drug Portfolio
• Table 88 : Sanofi: Recent Developments, 2022
• Table 89 : Siemens Healthineers: Company Snapshot
• Table 90 : Siemens Healthineers: Financial Performance, FY 2022 and 2023
• Table 91 : Siemens Healthineers: Prostate Cancer Product Portfolio
• Table 92 : Siemens Healthineers: Recent Developments, 2022-2023
• Table 93 : Abbreviations Used in this Report

List of Figures

• Summary Figure A : Global Market for Prostate Cancer Care, by Type, 2020-2028
• Summary Figure B : Global Market Shares of Prostate Cancer Care, by Type, 2022
• Figure 1 : Cancer Care Spectrum
• Figure 2 : Prostate Cancer Risk Group
• Figure 3 : Prostate Cancer Advancements
• Figure 4 : Prostate Cancer Care Market Dynamics
• Figure 5 : Estimated Number of New Prostate Cancer Cases, by Region, 2020 and 2040
• Figure 6 : Share of Prostate Cancer Cases, by Stage
• Figure 7 : Prostate Cancer Incidence in the U.S.
• Figure 8 : Cancer Radiotherapy Systems Treatment, by Region, 2021
• Figure 9 : Prostate Cancer 5-Year Relative Survival Rates
• Figure 10 : Trends in Oncology
• Figure 11 : Global Market for Prostate Cancer Screening and Detection, by Test Type, 2020-2028
• Figure 12 : Global Market Shares of Prostate Cancer Screening and Detection, by Test Type, 2022
• Figure 13 : Benefits of Immunotherapy
• Figure 14 : Global Market for Prostate Cancer Pharmaceuticals, by Drug Type, 2020-2028
• Figure 15 : Global Market Shares of Prostate Cancer Pharmaceuticals, by Drug Type, 2022
• Figure 16 : Global Market Shares of Hormone Therapy Drugs for Prostate Cancer, by Drug Type, 2022
• Figure 17 : Global Market Shares of Targeted Therapy Drugs for Prostate Cancer, by Drug Type, 2022
• Figure 18 : Global Market for Radical Prostatectomy, 2020-2028
• Figure 19 : Types of Radiation
• Figure 20 : Global Market for Radiation Therapy Devices for Prostate Cancer, by Treatment Type, 2020-2028
• Figure 21 : Global Market Shares of Radiation Therapy Devices for Prostate Cancer, by Treatment Type, 2022
• Figure 22 : Snapshot of Global Market for Prostate Cancer Screening, Diagnosis and Treatment, by Region
• Figure 23 : Global Market Shares of Prostate Cancer Screening, Diagnosis and Treatment, by Region, 2022
• Figure 24 : Estimated Number of Prostate Cancer Cases in the U.S., Both Sexes, 2020 to 2040
• Figure 25 : North American Market for Prostate Cancer Care, by Product Type, 2020-2028
• Figure 26 : European Market for Prostate Cancer Care, by Product Type, 2020-2028
• Figure 27 : Worldwide Distribution of New Prostate Cancer Cases, by Region, 2020-2040
• Figure 28 : Asia-Pacific Market for Prostate Cancer Care, by Product Type, 2020-2028
• Figure 29 : RoW Market for Prostate Cancer Care, by Product Type, 2020-2028
• Figure 30 : Emerging Technologies in Prostate Cancer Care
• Figure 31 : Active Clinical Trials in Phase 2 or 3 for Prostate Cancer, by Cancer Type, as of November 2023
• Figure 32 : Share of Active Clinical Trials in Phase 2 or 3 for Castration-Resistant Prostate Cancer (CRPC), by Cancer Type, as of November 2023
• Figure 33 : Global Market Share of Prostate Cancer Pharmaceutical, by Company, 2022
• Figure 34 : Abbott: Revenue Share, by Business Unit, FY 2022
• Figure 35 : Abbott: Revenue Share, by Region, FY 2022
• Figure 36 : Accuray Inc.: Revenue Share, by Product Type, FY 2023
• Figure 37 : Accuray Inc.: Revenue Share, by Region, FY 2023
• Figure 38 : Astellas Pharma Inc.: Revenue Share, by Product, 2022
• Figure 39 : Astellas Pharma Inc.: Revenue Share, by Region, 2022
• Figure 40 : AstraZeneca Plc: Revenue Share, by Therapy Area, 2022
• Figure 41 : AstraZeneca Plc: Revenue Share, by Region, 2022
• Figure 42 : Bayer AG: Revenue Share, by Business Segment, 2022
• Figure 43 : Bayer AG: Revenue Share, by Region, 2022
• Figure 44 : Danaher Corp.: Market Share, by Business Segment, 2022
• Figure 45 : Danaher Corp.: Revenue Share, by Region, 2022
• Figure 46 : Elekta: Revenue Share, by Product Type, 2023
• Figure 47 : Elekta: Revenue Share, by Region, 2023
• Figure 48 : F. Hoffmann-La Roche Ltd.: Market Share, by Business Segment, 2022
• Figure 49 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Region, 2022
• Figure 50 : Johnson & Johnson Services, Inc.: Revenue Share, by Business Segment, 2022
• Figure 51 : Johnson & Johnson Services, Inc.: Revenue Share, by Region, 2022
• Figure 52 : Pfizer Inc.: Revenue Share, by Business Unit, 2022
• Figure 53 : Pfizer Inc.: Revenue Share, by Region, 2022
• Figure 54 : Sanofi: Revenue Share, by Global Business Unit, 2022
• Figure 55 : Sanofi: Revenue Share, by Region, 2022
• Figure 56 : Siemens Healthineers: Revenue Share, by Segment, 2023
• Figure 57 : Siemens Healthineers: Revenue Share, by Region, 2023

Highlights:

The global market for prostate cancer care is expected to grow from $37.9 billion in 2023 to $56.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.3% from 2023 through 2028.

The global market for prostate cancer pharmaceuticals is expected to grow from $17.5 billion in 2023 to $29.6 billion by the end of 2028, at a CAGR of 11.0% from 2023 through 2028.

The global market for prostate cancer screening and detection is expected to grow from $15.0 billion in 2023 to $19.8 billion by the end of 2028, at a CAGR of 5.8% from 2023 through 2028.

Report Scope:

This research study analyzes the state of prostate cancer care, including screening, detection and treatment, offers revenue forecasts, assesses future trends, and provides recommendations for the success of market participants. The scope of the study is global. This report estimates market data for 2022 (the base year) and provides forecasts for 2023 through 2028. Figures for 2023 are estimated, except where actual results have been reported. This report includes forecasts by product type and region from 2023 through 2028. Genetic testing for inherited prostate cancer risk assessment is beyond the scope of the report.

Report Includes:

• 31 data tables and 63 additional tables
• An overview of the global market for the technologies for prevention and treatment of prostate cancer
• Analysis of global market trends, featuring historical revenue data for 2020-2022, estimated figures for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028
• Evaluation of the current market size and revenue growth prospects specific to prevention and treatment of prostate cancer, accompanied by a market share analysis by test type, treatment type, drug type and geographic region
• Description of several types of prostate cancer, namely acinar adenocarcinoma, ductal adenocarcinoma, transitional cell (or urothelial) cancer, small cell prostate cancer and carcinoid and sarcomas
• Description of biomarker tests such as the prostate-specific antigen (PSA) test, digital rectal exam (DRE) and prostate biopsy, and a discussion on their advantages and limitations
• Information on poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, their limitations and approvals related to their use as targeted therapy for prostate cancer
• Coverage of approvals for metastatic castration resistant prostate cancer (mCRPC), and collaborations and licensing agreements for the treatment of prostate cancer
• Evaluation of the current and future market potential and an analysis of the regulatory framework and reimbursement scenarios
• Review of patents, product pipelines, ESG trends and emerging technologies related to prevention and treatment of prostate cancer
• Market share analysis of the key companies in the industry and coverage of mergers & acquisitions, joint ventures, collaborations, partnerships and other market strategies
• Profiles of leading market participants

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing this Study
• Scope of Report
• What's New in this Update?
• Methodology and Information Sources
• Geographic Breakdown
• Segmentation Breakdown

Chapter 2 Summary and Highlights

• Market Outlook
• Market Summary

Chapter 3 Market Overview

• Overview of Cancer
• Prostate Cancer
• Biology of Prostate Cancer
• Symptoms
• Screening
• Diagnosis
• Localized Prostate Cancer
• Metastatic Prostate Cancer
• Watchful Waiting or Active Surveillance
• Treatment
• Conclusions

Chapter 4 Market Dynamics

• Overview
• Market Drivers
• Increasing Prevalence of Prostate Cancer
• Active Surveillance and Screening
• Personalized Care
• Approvals for Metastatic Castration-Resistant Prostate Cancer
• Collaborations and Licensing Agreements
• Market Challenges
• Loss of Exclusivity and Genericization
• Shortage of Care Providers and Other Resources
• Market Opportunities

Chapter 5 Screening and Diagnosis Market by Test Type

• Market Overview
• Biomarker Tests
• PSA Tests
• Limitations of PSA Tests
• Biomarker Tests for Early Prostate Cancer Detection in Elevated PSA Settings
• Digital Rectal Exam
• Limitations of DREs
• Prostate Biopsy
• Grade (Gleason Score) of Prostate Cancer
• Prostatic Intraepithelial Neoplasia
• Atypical Small Acinar Proliferation
• Proliferative Inflammatory Atrophy
• Intraductal Carcinoma of the Prostate
• Limitations of Prostate Biopsies
• Imaging Technologies for Prostate Cancer
• Market for Prostate Cancer Screening/Diagnosis, by Test Type
• Biomarker Tests
• DREs
• Prostate Biopsies

Chapter 6 Pharmaceuticals Market by Drug Type

• Market Overview
• Hormone Therapy
• Androgen Deprivation Therapy
• Antiandrogen Therapies
• Hormone Therapy Uses in Prostate Cancer Treatment
• Targeted Therapy
• PARP Inhibitors
• Radioligand Therapies
• Small Molecule Targeted Agents
• Monoclonal Antibodies
• Chemotherapy
• Immunotherapy
• Market Revenue, by Drug Type
• Hormone Therapy
• Targeted Therapy
• Immunotherapy
• Chemotherapy

Chapter 7 Market for Surgery and Radiation Therapy by Treatment Type

• Market Overview
• Active Surveillance
• Radical Prostatectomy
• Robotic Prostatectomy
• Open Radical Prostatectomy
• Laparoscopic Prostatectomy
• Radical Prostatectomy Market Revenue
• Radiation Therapy
• External Beam Radiation Therapy
• Brachytherapy
• Combined Radiation Therapy
• Radiation Therapy Device Market Revenue

Chapter 8 Market Breakdown by Region

• Market Overview
• Market Revenue, by Region
• North America
• Market Revenue, by Product Type
• Europe
• Market Revenue, by Product Type
• Asia-Pacific
• Market Revenue, by Product Type
• Rest of the World (RoW)
• Market Revenue, by Product Type

Chapter 9 Emerging Technologies and Developments

• Overview
• Liquid Biopsy
• Multiparametric MRI
• Homologous Recombination Repair Gene Mutation
• Advanced Radiotherapy Techniques
• AI and Machine Learning

Chapter 10 Pipeline Analysis

• Overview
• By Company

Chapter 11 Competitive Intelligence

• Overview
• Screening and Diagnosis Market
• Market for Radiation Therapy Devices
• Pharmaceuticals Market

Chapter 12 Company Profiles

• ABBOTT
• ACCURAY INC.
• ASTELLAS PHARMA INC.
• ASTRAZENECA PLC
• BAYER AG
• DANAHER CORP.
• DENDREON PHARMACEUTICALS LLC
• ELEKTA
• F. HOFFMANN-LA ROCHE LTD.
• JOHNSON & JOHNSON SERVICES INC.
• PFIZER INC.
• SANOFI
• SIEMENS HEALTHINEERS AG

Chapter 13 Appendix: Abbreviations